Welcome to our dedicated page for Alterity Therapeutics news (Ticker: ATHE), a resource for investors and traders seeking the latest updates and insights on Alterity Therapeutics stock.
Alterity Therapeutics Limited develops treatments for neurodegenerative diseases, with a clinical program centered on Multiple System Atrophy and related Parkinsonian disorders. News about ATHE commonly covers ATH434, its lead MSA candidate, Phase 2 analyses, FDA interactions, chemistry, manufacturing and control updates, and presentations at neurology and imaging conferences.
Coverage also includes bioMUSE Natural History Study biomarker work, including quantitative susceptibility mapping MRI for iron dysregulation in MSA, Appendix 4C cash flow and corporate updates, board appointments, and discussions of the company’s drug discovery platform for patentable chemical compounds targeting neurological disease pathology.
Alterity Therapeutics (ATHE) will participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026 on Friday, September 11, 2026 at 10:20 a.m. ET.
The live and archived webcast will be available via the Investors > Events and Presentations section of the company’s website. Alterity is a clinical stage biotechnology company developing disease modifying therapies for neurodegenerative diseases, with a focus on Multiple System Atrophy (MSA) and related Parkinsonian disorders. The company is preparing to initiate a Phase 3 pivotal trial in MSA with its lead asset ATH434, which has shown clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial and positive data in an open label Phase 2 trial in participants with advanced MSA.
Alterity Therapeutics (NASDAQ: ATHE) announced that the U.S. Patent and Trademark Office has granted a new U.S. composition of matter patent covering a crystalline mesylate form of ATH434, its lead oral candidate for neurodegenerative diseases including Multiple System Atrophy (MSA) and Parkinson’s disease.
The patent protects both the crystalline form and methods of treating neurological conditions using it, extends ATH434 protection to at least 2045, and is expected to be listed in the FDA Orange Book if ATH434 is approved. According to Alterity, this strengthens multi-layered market protection, supports planned Phase 3 development in MSA by year-end 2026, and enables future development opportunities in Parkinson’s disease and other disorders involving iron dysregulation and protein aggregation. ATH434 has previously shown clinically meaningful efficacy and favorable safety in Phase 2 MSA trials and holds FDA Fast Track and Orphan Drug designations, as well as Orphan status from the European Commission.
Alterity Therapeutics (NASDAQ: ATHE, ASX: ATH) announced that CEO David Stamler, M.D., will present at the 46th Annual Canaccord Genuity Growth Conference on Tuesday, August 11, 2026 at 1:30 p.m. ET in the United States.
A live and archived webcast of the presentation will be available via the Investors > Events and Presentations section of Alterity’s website. Alterity is a clinical-stage biotechnology company focused on disease-modifying therapies for Multiple System Atrophy (MSA) and related Parkinsonian disorders, with lead asset ATH434 having shown clinically meaningful efficacy in a Phase 2 trial.
Alterity Therapeutics (NASDAQ: ATHE, ASX: ATH) reported its Q4 FY26 Appendix 4C and corporate update, highlighting FDA End-of-Phase 2 meeting minutes that confirm a registrational pathway for ATH434 in Multiple System Atrophy. According to Alterity, the FDA indicated that a single pivotal Phase 3 trial plus confirmatory evidence, expected from the Phase 2 ATH434-201 study, could support an NDA.
The planned Phase 3 trial is expected to enroll ~200 MSA patients, randomized 1:1 to ATH434 50 mg or placebo twice daily for 12 months, with an open-label extension. The company strengthened scientific positioning through multiple presentations and a NeuroImage publication validating QSM MRI iron mapping as an MSA biomarker.
Alterity reported a cash balance of A$37.3 million as of 30 June 2026, quarterly operating cash outflows of A$7.72 million, and receipt of an A$3.98 million Australian R&D Tax Incentive refund after quarter end. The company completed a 1-for-50 share consolidation and appointed Ann Cunningham as an independent non-executive director while continuing to evaluate strategic funding and partnering options for Phase 3.
Alterity Therapeutics (NASDAQ: ATHE, ASX: ATH) announced that CEO David Stamler, M.D., will participate in the virtual BTIG Biotechnology Conference 2026, to be held 28-29 July 2026, hosting 1-on-1 meetings with U.S. investors.
Alterity is a clinical-stage company focused on Multiple System Atrophy (MSA) and related Parkinsonian disorders. The company is preparing a Phase 3 pivotal trial of lead asset ATH434, which has shown clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 MSA study and positive data in an open-label Phase 2 trial in advanced MSA.
Alterity Therapeutics (NASDAQ: ATHE) received official FDA End-of-Phase 2 meeting minutes for ATH434 in Multiple System Atrophy (MSA), confirming the key elements of its registrational Phase 3 program.
The FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support a potential NDA for ATH434, with trial activities expected to begin by year-end 2026.
The planned Phase 3 will enroll about 200 patients, randomized 1:1 to ATH434 50 mg or placebo for 12 months, using the 11-item UMSARS Part I as the primary endpoint and several symptom-focused scales as key secondary endpoints.
Alterity Therapeutics (NASDAQ: ATHE) reported a successful End-of-Phase 2 meeting with the U.S. FDA for its MSA candidate ATH434, securing FDA alignment on the pivotal Phase 3 program design.
The FDA agreed on the study population, 50 mg twice-daily dosing, treatment duration, and primary endpoint UMSARS Part I, after Phase 2 data showed 48% slowing of disease progression versus placebo. Key secondary endpoints and statistical methods were also accepted, and the Phase 3 program is intended to support a potential NDA. ATH434 already holds Fast Track and Orphan Drug designations for MSA. Trial activities are planned to begin by year-end 2026.
Alterity Therapeutics (NASDAQ:ATHE) reported new data supporting advancement of ATH434 into Phase 3 for Multiple System Atrophy (MSA). Phase 2 analyses showed statistically significant slowing of functional decline at 50 mg BID (~48% reduction) and benefits on swallowing, alongside MRI and CSF biomarker evidence of target engagement.
An End-of-Phase 2 FDA meeting is planned for mid-2026 to confirm the Phase 3 path, supported by quantitative susceptibility mapping (QSM) and CSF NfL-based patient stratification.
Alterity Therapeutics (NASDAQ:ATHE) reported a peer-reviewed NeuroImage publication from its bioMUSE study showing quantitative susceptibility mapping (QSM) MRI detects disease-specific brain iron accumulation in Multiple System Atrophy, distinguishes MSA from Parkinson’s disease, and correlates with clinical severity. Alterity is advancing ATH434 toward a pivotal Phase 3 program, with FDA End-of-Phase 2 meeting targeted for mid-2026.
Alterity Therapeutics (NASDAQ: ATHE) announced multiple May 2026 medical conference presentations on its Multiple System Atrophy (MSA) development program.
Presentations include ISMRM (May 12, Cape Town), MDSANZ (May 15-17, Sydney) and MSA Symposium (May 18, London), featuring data and a clinical update on ATH434.